Taner C Burcin, Balci Deniz, Willingham Darrin L, Keaveny Andrew P, Rosser Barry G, Canabal Juan M, Shine Timothy S J, Harnois Denise M, Kramer David J, Nguyen Justin H
Department of Transplantation, Mayo Clinic Florida, Jacksonville, FL 32224, USA.
Exp Clin Transplant. 2011 Apr;9(2):98-104.
Orthotopic liver transplant is the treatment of choice for patients with end-stage liver disease. Patients with first graft failure requiring liver retransplant are commonly seen at most liver transplant centers. However, patients with a second graft failure requiring a third graft are uncommon. Liver retransplant in this setting has only been pursued at a few large transplant centers.
This is a retrospective analysis of the long-term outcomes of recipients who underwent 3 or more orthotopic liver transplants. Between February 1998 and August 2009, 24 patients had 3 or more orthotopic liver transplants at the Mayo Clinic in Florida.
Mean patient survival was 103.8 months for the study cohort. Actuarial patient survival after the last orthotopic liver transplant in -1, -5, and -10 years was 60%, 40%, 33%. Patients were transplanted with lower donor risk index score grafts in each subsequent orthotopic liver transplant. Patients who had a graft with a donor risk index score > 1.6 at the time of the third orthotopic liver transplant had significantly lower survival rate compared with those with grafts with a donor risk index score ≤ 1.6.
Multiple liver retransplants offer acceptable patient survival. Each transplant program must decide whether to do multiple orthotopic liver transplants based on the program's transplant volume and outcomes to help this subgroup of patients. The concerns of potentially decreasing access to first time orthotopic liver transplant candidates should also be weighed in the decision to move forward.
原位肝移植是终末期肝病患者的首选治疗方法。大多数肝移植中心常见首次移植失败需要再次肝移植的患者。然而,第二次移植失败需要第三次移植的患者并不常见。这种情况下的肝再次移植仅在少数大型移植中心开展。
这是一项对接受3次或更多次原位肝移植受者长期结局的回顾性分析。1998年2月至2009年8月期间,24例患者在佛罗里达州的梅奥诊所接受了3次或更多次原位肝移植。
研究队列的平均患者生存期为103.8个月。最后一次原位肝移植后1年、5年和10年的患者精算生存率分别为60%、40%、33%。在每次后续原位肝移植中,患者接受的供体风险指数评分较低的移植物。第三次原位肝移植时供体风险指数评分>1.6的移植物患者的生存率明显低于供体风险指数评分≤1.6的移植物患者。
多次肝再次移植可提供可接受的患者生存率。每个移植项目必须根据项目的移植量和结局来决定是否进行多次原位肝移植,以帮助这一亚组患者。在做出推进决定时,还应权衡可能减少首次原位肝移植候选者获得移植机会的担忧。